[Therapy of non-steroidal antirheumatic drug-induced gastrointestinal lesions with misoprostol].
In a multicenter placebo-controlled double-blind study in patients with degenerative or inflammatory rheumatic diseases the prostaglandin analogue misoprostol, in a dose of 200 micrograms twice daily after meals, was administered for the treatment of NSAID-induced lesions and symptoms of the upper gastrointestinal tract. Treatment with an NSAID was continued. Misoprostol treatment was demonstrated to be clearly superior to placebo in respect of reduction of gastroduodenal lesions and gastrointestinal pain. In addition, the physician's global assessment of gastrointestinal complaints was also statistically significantly better. No difference between the groups was found with respect to antirheumatic action of the NSAIDs.
Klinik Herzoghöhe - Innere Medizin und Rheumatologie, Bayreuth.
G L
GL
Bach
K P
KP
Stock
M
M
Hüdepohl
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000139:chemically induced* / Q000188:drug therapy; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D016595:Misoprostol / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D016595:Misoprostol
Die Therapie NSAR-induzierter gastrointestinaler Läsionen mit Misoprostol.